Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
Por:
Jabbour, E, Martinelli, G, Vignetti, M, Kantarjian, H, Gomez-Almaguer, D, Minami, Y, Dombret, H, Hennessy, M, Vorog, A, Wang, BX and Ribera, JM
Publicada:
1 sep 2021
Resumen:
Filiaciones:
Jabbour, E:
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
Martinelli, G:
IRCCS Ist Romagnolo Studio Tumori Dino Amadori IR, Meldola, Italy
Vignetti, M:
GIMEMA Res Fdn, Rome, Italy
Kantarjian, H:
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
Gomez-Almaguer, D:
UANL, Univ Hosp, Monterrey, Nuevo Leon, Mexico
Minami, Y:
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
Dombret, H:
Univ Paris, Inst Rech St Louis, Hop Sain Louis, Paris, France
Hennessy, M:
Millennium Pharmaceut Inc, Cambridge, MA USA
Vorog, A:
Millennium Pharmaceut Inc, Cambridge, MA USA
Wang, BX:
Millennium Pharmaceut Inc, Cambridge, MA USA
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Josep Carreras Res Inst, Badalona, Spain
|